Zak Mir talks to Tim McCarthy, CEO Immupharma, in the wake of the specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, announcing the filing of a groundbreaking new patent application for its lead asset P140, the world’s first “Immunormalizer.”